Northwest Biotherapeutics, Inc.
NWBO
$0.19
-$0.01-4.43%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -3.07M | 1.39M | -26.83M | -15.38M | -19.34M |
| Total Depreciation and Amortization | 847.00K | 801.00K | 521.00K | 517.00K | 498.00K |
| Total Amortization of Deferred Charges | 277.00K | 614.00K | 414.00K | 525.00K | 334.00K |
| Total Other Non-Cash Items | -8.67M | -16.63M | 9.35M | 2.78M | 2.71M |
| Change in Net Operating Assets | -1.89M | -936.00K | 2.65M | 4.87M | 6.38M |
| Cash from Operations | -12.51M | -14.76M | -13.89M | -6.69M | -9.42M |
| Capital Expenditure | -129.00K | -905.00K | -202.00K | -304.00K | -93.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 0.00 | -311.00K | -- | -- |
| Cash from Investing | -129.00K | -905.00K | -513.00K | -304.00K | -93.00K |
| Total Debt Issued | 7.47M | 11.57M | 7.18M | 5.31M | 7.20M |
| Total Debt Repaid | -500.00K | 0.00 | -479.00K | -184.00K | -607.00K |
| Issuance of Common Stock | 2.91M | 2.02M | 4.86M | 7.33M | 5.14M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -666.00K | -- | -- | -- | -- |
| Cash from Financing | 9.21M | 13.59M | 11.56M | 12.45M | 11.73M |
| Foreign Exchange rate Adjustments | 2.18M | 561.00K | 3.09M | -3.92M | -1.62M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.25M | -1.52M | 244.00K | 1.54M | 604.00K |